Jeff Davis advises healthcare organizations on Medicare and Medicaid billing and reimbursement issues, with a special focus on the federal 340B drug pricing program. He also counsels clients on emerging healthcare regulatory issues, including COVID-19 relief funding, surprise medical billing, and hospital price transparency, and provides strategic insights to clients on public policy matters under consideration by the U.S. Congress and federal agencies, such as drug pricing policy and nonprofit hospital issues.
Jeff forged his deep knowledge of the 340B program and other Medicare and Medicaid reimbursement issues while working in the federal public policy arena. He spent more than seven years working as vice president and legislative and policy counsel for 340B Health, an association of more than 1,400 hospitals and health systems participating in the 340B program. In this role, he provided technical assistance to member hospitals, directed research and policy efforts, and helped lead government relations efforts to educate federal policy makers on 340B issues. He draws on this experience to advise hospitals, pharmacies, other provider organizations and vendors on 340B issues including enrollment, contracting, audits, compliance and self-disclosures.
Before his work at 340B Health, he was the healthcare legislative assistant to U.S. Representative Shelley Berkley (D-NV), where he worked with healthcare provider companies to promote increased Medicare funding for a range of organizations, including hospitals, physicians and post-acute providers.
Jeff is a frequent speaker on the 340B program for conferences and webinars organized by the American Health Law Association, the 340B Coalition, other national provider groups and state hospital associations.
While many 340B stakeholders hoped last year’s federal court decision in the Genesis case regarding the definition of a 340B-eligible “patient” would resolve ongoing uncertainty about when 340B covered entities can use discounted dr...